Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides TeloView-SMM application; TeloView, an analysis software platform for prediction of genomic instability. It has a collaboration agreement with the Mayo Clinic to validate its SMM tests for multiple myeloma. Telo Genomics Corp. is headquartered in Toronto, Canada.
Stock data | 2023 | Change |
---|---|---|
Price | $0.08350440137782263 | N/A |
Market Cap | $5.02M | N/A |
Shares Outstanding | 60.15M | 2.54% |
Employees | 0 | N/A |
Shareholder Equity | 2.61M | 0.37% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -1.67 | N/A |
P/B Ratio | 1.92 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.7513 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $0 | N/A |
Earnings | -$1.96M | N/A |
EPS | -0.05 | N/A |
Earnings Yield | -0.5988 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $2.04M | N/A |
Cash on Hand | $1.86M | N/A |
Debt to Equity | 0.0833 | 35.49% |
Current Ratio | $10.14 | -30.83% |